Our Medical Weight Management® Library (FAQ’S)
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
Memorial Day Pre-Sale: Train 2 injectors for the price of 1! Aesthetic Medicine Symposium (June 5-8, 2026) in Scottsdale, AZ. Limited spots available!
Memorial Day Botox Training Sale: Train 2 injectors for the price of 1!
June 5-8, 2026 in Scottsdale, AZ
Plus… special $97++/night hotel rates available.
You’re not alone, and you’re almost certainly not doing anything wrong. Why am I not losing weight on Ozempic®? is one of the most common questions GLP-1 patients ask their providers, and the answer is rarely just one thing. Semaglutide is a remarkably effective medication, but it works inside a body that has its own biology, hormones, sleep patterns, stress load, and history with food. When weight loss stalls, the cause is usually a combination of factors — most of which can be adjusted with the right plan.
This guide walks through the 12 most common reasons GLP-1 weight loss stalls, what the research actually shows about expected results, why some patients gain weight on Ozempic®, and what to discuss with your provider before changing your treatment plan.
In the landmark STEP 1 trial published in the New England Journal of Medicine, adults taking 2.4 mg of semaglutide weekly lost an average of 14.9% of their starting body weight over 68 weeks, compared to just 2.4% in the placebo group. About 86% of participants lost at least 5% of body weight, and roughly one in three lost 20% or more.
Those are remarkable results. But the word average is doing a lot of work. Some participants lost more than 25%. Others lost less than 5%. Individual response varies widely — and that variation is the starting point for understanding why your scale may not be moving.
This is the single most common reason patients stall early. Ozempic® is titrated up over months: typically 0.25 mg for four weeks, then 0.5 mg for at least four weeks, then 1 mg, and (when prescribed for weight loss off-label) sometimes higher.
The lower doses are designed to minimize nausea and other side effects — not to drive weight loss. Most patients don’t see meaningful, sustained weight loss until they reach 1 mg or higher. If you’ve been at 0.25 mg or 0.5 mg for a few months and the scale isn’t moving, the medication isn’t failing — you simply haven’t reached the dose where it works for your body yet.
What to do: Talk to your provider about your titration schedule and whether it’s appropriate to move to the next dose.
Ozempic® reduces appetite, but it doesn’t override the laws of energy balance. To lose fat, you still need to consume fewer calories than you burn.
What surprises many patients is how easy it is to not be in a deficit even when eating less. Smaller portions of calorie-dense, highly processed foods can still add up to maintenance calories or more. A handful of nuts, a tablespoon of nut butter, salad dressings, oils, cheese, and “healthy” snacks like granola can quietly account for hundreds of unaccounted calories.
What to do: Track your intake honestly for one to two weeks (most people significantly underestimate). A registered dietitian or your medical weight loss provider can help calibrate the right calorie target for your body.
GLP-1 medications work largely by making solid food less appealing and by stretching out fullness from your last meal. Liquid calories — smoothies, juice, sweetened coffee drinks, soda, alcohol — bypass much of that mechanism.
Liquid calories don’t trigger the same satiety signals as solid food, and alcohol in particular has been shown to lower inhibitions around food, slow fat burning, and disrupt sleep. A daily 200-calorie latte and a glass of wine with dinner can erase most of an Ozempic®-induced deficit.
What to do: Audit what you drink. Replace sweetened beverages with water, sparkling water, unsweetened tea, or black coffee. If you drink alcohol, consider reducing frequency rather than portion size.
This is one of the most overlooked reasons GLP-1 weight loss stalls. When appetite drops sharply, many patients end up eating very little — and what little they eat is often whatever’s easiest: crackers, soup, fruit, toast.
The result: not enough protein to maintain muscle. Muscle is metabolically expensive, meaning it burns calories even at rest. When you lose muscle along with fat, your metabolism slows, making continued weight loss progressively harder.
Most weight-loss specialists recommend at least 0.7 to 1 gram of protein per pound of goal body weight while on a GLP-1, prioritizing protein at every meal — even when you don’t feel like eating much.
What to do: Front-load protein. Aim for 25–40 grams at breakfast (Greek yogurt, eggs, cottage cheese, protein shakes) before appetite suppression peaks later in the day.
Recent research suggests that up to 39% of the weight lost on semaglutide can come from lean mass, including muscle. This isn’t unique to GLP-1s — any rapid weight loss method causes some lean mass loss — but the combination of low appetite and reduced food intake makes it especially common with Ozempic®.
Why this matters for the scale: muscle loss reduces your basal metabolic rate (the calories you burn just by being alive). Over months, that adds up to needing meaningfully fewer calories to maintain weight, which makes plateaus more likely and rebounds more probable if you stop the medication.
What to do: Add resistance training (two to three sessions per week of weights, bands, or bodyweight strength work) and pair it with adequate protein. This is the single most evidence-backed way to preserve muscle while losing fat.
Plateaus are a normal, predictable part of weight loss — with or without medication. As you lose weight, your body needs fewer calories to function. Your hormones (leptin, ghrelin, thyroid hormone) shift to encourage you to eat more and burn less. This is called metabolic adaptation, and it’s a survival mechanism that has nothing to do with willpower.
For most GLP-1 patients, weight loss is fastest in the first three to six months, slows in months six to twelve, and approaches a plateau somewhere between months twelve and eighteen. Many clinical trials show this pattern clearly: a steep initial drop, then a gradual flattening of the curve.
What to do: Plateaus that last two to four weeks are normal. Plateaus longer than six to eight weeks are worth a conversation with your provider about dose adjustments, food and movement changes, or whether to switch medications.
Sleep deprivation and chronic stress sabotage weight loss in measurable ways. Just one week of sleeping fewer than six hours per night raises the hunger hormone ghrelin, lowers the satiety hormone leptin, and increases cortisol — a combination that promotes fat storage (especially around the abdomen) and increases cravings for high-calorie foods.
Chronic stress has a similar effect. High cortisol over long periods is linked to insulin resistance and stubborn belly fat that resists even strong calorie deficits.
What to do: Aim for seven to nine hours of sleep nightly. Consider a sleep study if you snore or wake up tired — sleep apnea is dramatically underdiagnosed in people carrying excess weight, and it directly blocks weight loss progress. Manage stress with whatever works for you: walks, breathwork, therapy, time off screens.
Several common medical conditions interfere with weight loss regardless of medication:
What to do: If you’ve been on Ozempic® for several months at a therapeutic dose without progress, ask your provider for a comprehensive workup: TSH, free T3, free T4, fasting insulin, A1C, cortisol, and (for women) a hormone panel.
What to do: Never stop a prescribed medication without your provider’s input. But do bring a complete list of everything you take to your weight-loss visits — sometimes a simple substitution within the same drug class can make a meaningful difference.
Roughly 10–15% of patients are clinically considered “non-responders” to semaglutide — meaning they lose less than 5% of body weight even at the maximum dose with good adherence. Genetic differences in GLP-1 receptors, gut hormone signaling, and other factors are still being studied.
The good news: not responding to semaglutide doesn’t mean you’ll fail every GLP-1. Tirzepatide (Mounjaro® for diabetes, Zepbound® for weight loss) targets both GLP-1 and GIP receptors and produces meaningfully greater average weight loss in head-to-head studies. The SURMOUNT-5 trial showed tirzepatide led to about 20% body weight loss versus about 14% on semaglutide over 72 weeks.
What to do: If you’ve genuinely tried Ozempic® for 12–16 weeks at the highest tolerated dose with consistent adherence and aren’t seeing results, ask your provider whether switching to tirzepatide makes sense for you.
Three to four weeks at a new dose is rarely enough time to evaluate it. Most providers won’t make a meaningful judgment call until 12 to 16 weeks at the therapeutic dose — and clinical trials measure outcomes at 68 to 72 weeks.
Weight loss isn’t linear. Two-week stalls happen routinely (often related to menstrual cycles, sodium, sleep, or simple measurement noise). What matters is the trend over months, not the number on any single morning.
What to do: Track your trend with weekly averages, not daily weights. Use other markers too: how clothes fit, body measurements, energy, sleep, and labs.
If you’re using compounded semaglutide rather than brand-name Ozempic® or Wegovy®, the dose and quality you’re getting can vary significantly between pharmacies. The FDA has issued warnings about counterfeit semaglutide and has flagged dosing errors and contamination concerns with some compounded versions.
Following the FDA’s resolution of the official semaglutide shortage, large-scale compounding of semaglutide has been substantially restricted. If you’re still receiving compounded versions, it’s worth confirming the source and the legal basis your prescriber is using.
What to do: Confirm where your medication is sourced. If you’re on compounded semaglutide and not seeing results, switching to brand-name product (where possible) eliminates one major variable.
Sign up today and expand your knowledge & skills in Botox®, Fillers, Lasers,
Chemical Peels, Microdermabrasion and PRP for Aesthetics!
This is one of the most-asked questions in GLP-1 weight loss, and the honest answer is: it depends on your starting weight, dose, adherence, and individual biology. Here’s what the research shows:
For someone starting at 200 pounds, 14.9% works out to roughly 30 pounds — over more than a year, not a few months. Quick math like this is helpful for setting realistic expectations.
It’s also normal for weight loss to slow over time. Most patients lose the largest share in the first six months, then continue losing more slowly for several months before approaching a plateau.
| Medication / Dose | Average Weight Loss | Timeframe |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy®) — STEP 1 trial | ~14.9% of starting body weight | 68 weeks |
| Semaglutide 1.0 mg (Ozempic®, off-label for weight loss) | ~5–10% of starting body weight | 6–12 months |
| Tirzepatide 15 mg (Zepbound®) — SURMOUNT-1 | ~20.9% of starting body weight | 72 weeks |
| Placebo + lifestyle changes | ~2.4% of starting body weight | 68 weeks |
Less common, but genuinely distressing when it happens. A few patients gain weight on Ozempic® despite consistent dosing. The most likely explanations:
If you’re consistently gaining weight despite proper dose titration and adherence, this is the moment to schedule a thorough medical review — not to abandon the medication on your own.
Schedule a follow-up visit if any of the following apply:
A qualified medical weight loss provider should never simply tell you to “try harder.” A genuine review looks at your dose, adherence, food and movement patterns, sleep, stress, other medications, and bloodwork — and adjusts the plan based on what they find.
If your weight loss has stalled, here’s a practical action checklist before your next provider visit:
Most patients notice reduced appetite within the first one to two weeks, but visible scale changes typically take four to twelve weeks. The most meaningful weight loss usually starts after you reach a therapeutic dose (1 mg or higher), which can take three to four months from your first injection due to the required titration schedule.
Eating less doesn’t always mean eating few enough calories to be in a deficit, especially if you’re consuming calorie-dense foods or liquid calories. Other factors include muscle loss (which slows metabolism), inadequate protein, poor sleep, undiagnosed thyroid or hormonal issues, or simply needing more time at your current dose. A provider can help identify the specific factor for you.
Ozempic® is FDA-approved for type 2 diabetes, not weight loss. For weight management, Wegovy® (semaglutide 2.4 mg) is the FDA-approved option, typically prescribed for patients with a BMI of 30 or higher, or 27+ with a weight-related condition. Whether GLP-1 medication is appropriate for smaller amounts of weight loss depends on your overall health profile and should be discussed with your provider.
Most patients regain a meaningful portion of lost weight after stopping GLP-1 medications. The STEP 4 trial showed participants who stopped semaglutide regained roughly two-thirds of their lost weight within a year. This is why many providers and obesity specialists view GLP-1 medications as long-term treatment for a chronic condition (obesity), not a short-term reset.
Tirzepatide (Mounjaro® and Zepbound®) targets both GLP-1 and GIP receptors and has shown greater average weight loss in head-to-head trials. For non-responders to semaglutide, switching is a reasonable conversation to have with your provider — but it should follow a genuine evaluation of dose, adherence, and other factors first.
Ozempic® doesn’t typically lose its mechanism of action, but its visible effect on the scale slows over time as your body adapts metabolically. This is true of every weight-loss tool, including bariatric surgery. Continued progress past month six often requires renewed attention to protein, strength training, sleep, and (sometimes) a dose adjustment.
Current data supports semaglutide use for several years, and the FDA has approved it for chronic weight management. Long-term safety data continues to be collected. Side effects to monitor include gastrointestinal issues, gallbladder problems, pancreatitis (rare), and potential thyroid concerns (the medication carries a boxed warning related to thyroid C-cell tumors observed in rodent studies; relevance to humans is not fully established). Discuss your personal risk factors with your provider.
The single biggest factor in successful GLP-1 weight loss isn’t the medication itself — it’s the provider managing it. A well-trained medical weight loss provider will optimize your dose, evaluate underlying conditions, support your nutrition and exercise plan, and adjust your treatment when something isn’t working.
For more than 20 years, the International Association for Physicians in Aesthetic Medicine (IAPAM) has provided hands-on training to thousands of healthcare professionals — physicians, nurse practitioners, physician assistants, RNs, and dentists — in evidence-based aesthetic medicine and medical weight loss. Courses are taught at IAPAM’s Scottsdale, Arizona training clinic by board-certified dermatologists and other expert faculty, and IAPAM has earned more than 6,300 reviews at 4.9 stars from healthcare professionals who have completed its programs.
If you’re a patient: ask your prescribing provider what specific training they’ve completed in GLP-1 weight loss management. The right partner can be the difference between months of stalled progress and a treatment plan that actually works for your body.
If you’re a healthcare professional looking to add GLP-1 weight loss services to your practice, explore IAPAM’s CME-accredited GLP-1 Weight Loss Certification Training or the broader medical weight loss training resources. Many of the same providers who offer medical weight loss also expand into aesthetic medicine through programs like IAPAM’s hands-on Botox® training, including specialized tracks for Botox® training for nurse practitioners and physician Botox® certification. Free patient and provider resources are also available in the IAPAM Learning Library.
Disclaimer: This article is for informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers. Always consult a qualified healthcare provider before starting, stopping, or adjusting any medication.
Build an independent practice with direct patient relationships—not through corporate intermediaries.
Start offering GLP-1 services the day after training. Practices see $100K–$900K in additional annual revenue.
Renewable certification keeps you compliant with evolving FDA guidelines and latest treatment protocols.
Learn marketing, patient flow optimization, and practice-building strategies—not just clinical skills.
Join thousands of healthcare providers who’ve added profitable GLP-1 weight loss services to their practice. Choose from online, self-study certification or join us live in sunny Scottsdale, Arizona for our 1-day training session.
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.